These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38429311)

  • 1. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab.
    Chen B; Liu S; Zhu Y; Wang R; Cheng X; Chen B; Dragomir MP; Zhang Y; Hu Y; Liu M; Li Q; Yang H; Xi M
    Nat Commun; 2024 Mar; 15(1):1919. PubMed ID: 38429311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy.
    Wang Y; Wang W; Zhang T; Yang Y; Wang J; Li C; Xu X; Wu Y; Jiang Y; Duan J; Wang L; Bi N
    J Natl Cancer Cent; 2024 Jun; 4(2):177-187. PubMed ID: 39282582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
    Zhu Y; Wen J; Li Q; Chen B; Zhao L; Liu S; Yang Y; Wang S; Lv Y; Li J; Zhang L; Hu Y; Liu M; Xi M
    Lancet Oncol; 2023 Apr; 24(4):371-382. PubMed ID: 36990609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
    Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
    Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study.
    Wang R; Liu S; Chen B; Li Q; Cheng X; Zhu Y; Zhang L; Hu Y; Liu M; Hu Y; Xi M
    Br J Cancer; 2024 Sep; 131(4):709-717. PubMed ID: 38937623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
    Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
    Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial.
    Wang R; Ling Y; Chen B; Zhu Y; Hu Y; Liu M; Yang Y; Zhang L; Lv Y; Liu S; Li Q; Xi M
    EClinicalMedicine; 2024 Sep; 75():102806. PubMed ID: 39281099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
    Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
    Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma.
    Habu T; Kumanishi R; Ogata T; Fujisawa T; Mishima S; Kotani D; Kadowaki S; Nakamura M; Hojo H; Fujiwara H; Kumagai S; Koyama S; Fujita T; Kinoshita T; Nishikawa H; Yano T; Tajika M; Muro K; Mitsunaga S; Kojima T; Bando H
    Esophagus; 2023 Jul; 20(3):533-540. PubMed ID: 36750480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.
    Zhao Q; Hu G; Xiao W; Chen Y; Shen M; Tang Q; Ning X
    Medicine (Baltimore); 2017 Sep; 96(35):e7920. PubMed ID: 28858114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.
    Zhang T; Guo Z; Chen X; Dong J; Jiang H; Tang P; Wang P; Qian D; Zhang W; Pang Q
    Radiat Oncol; 2022 Aug; 17(1):148. PubMed ID: 35999608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.
    Yu N; Cheng G; Li J; Liang J; Zhang T; Deng L; Liu W; Wang J; Zhai Y; Wang W; Xiao Z; Zhou Z; Chen D; Feng Q; Bi N; Wang X
    Curr Cancer Drug Targets; 2023; 23(8):653-662. PubMed ID: 36924100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.
    Cheng X; Chen B; Wang S; Zhang J; Zhu J; Liu M; Liu S; Xi M
    Oncologist; 2023 Aug; 28(8):e606-e616. PubMed ID: 37061835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Chen MQ; Lin QL; Chen YG; Guo JH; Xu BH; Tian Y
    J Chin Med Assoc; 2017 Oct; 80(10):636-643. PubMed ID: 28716602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma.
    Chang WL; Lai WW; Kuo IY; Lin CY; Lu PJ; Sheu BS; Wang YC
    J Gastroenterol; 2017 Jun; 52(6):705-714. PubMed ID: 27671002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail.
    Meng X; Wang J; Sun X; Wang L; Ye M; Feng P; Zhu G; Lu Y; Han C; Zhu S; Liao Z; Yu J
    Radiother Oncol; 2013 Nov; 109(2):275-80. PubMed ID: 24128808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.